GeneDx Holdings stock: fair value
WGSThe fair value of GeneDx Holdings under our model is $32.43, the price is 60% above.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $21.62 and expensive above $64.86 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $27.20, at 8.4% it would be $39.95.
Where the number comes from
From the cash-flow model alone; without earnings there is no industry value.
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.8%. Discounted at 9.4% (government bond yield 3.8% plus beta 1.26 times a risk premium of 4.5%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $32.43 per share: free cash flow for the next ten years, each year discounted to today at 9.4%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 9.4%) |
|---|---|---|---|---|
| 2026 | $31.28M | extrapolated at 34.8% | 0.9137 | $28.58M |
| 2027 | $39.26M | extrapolated at 25.5% | 0.8349 | $32.78M |
| 2028 | $46.72M | extrapolated at 19.0% | 0.7629 | $35.64M |
| 2029 | $53.47M | extrapolated at 14.5% | 0.6971 | $37.27M |
| 2030 | $59.49M | extrapolated at 11.3% | 0.6369 | $37.89M |
| 2031 | $64.86M | extrapolated at 9.0% | 0.5820 | $37.75M |
| 2032 | $69.71M | extrapolated at 7.5% | 0.5318 | $37.07M |
| 2033 | $74.16M | extrapolated at 6.4% | 0.4859 | $36.03M |
| 2034 | $78.32M | extrapolated at 5.6% | 0.4440 | $34.77M |
| 2035 | $82.3M | extrapolated at 5.1% | 0.4057 | $33.39M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $351.16M |
| Terminal value: cash flow 2035 × (1 + 3.8%) / (9.4% − 3.8%) | $1.52B |
| Present value of terminal value (× 0.4057) | $617.78M |
| Equity value (sum plus present value of terminal value) | $968.94M |
| Shares (diluted) | 29.88M |
| Value per share (equity value divided by shares) | $32.43 |
| Fair value (from the cash flow model alone) | $32.43 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2021)
- Valuation signal Fairly valued since 11 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.